Skip to content

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05664802
Acronym
e-HERO
Enrollment
72
Registered
2022-12-27
Start date
2022-12-01
Completion date
2024-06-19
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus (HIV)

Keywords

Sexual and Gender Minorities; American Indian; HIV Testing

Brief summary

The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the e-HERO intervention.

Detailed description

In the U.S., incidence rates of HIV and sexually transmitted infections (STIs) are disproportionately high among gay, bisexual, and other men who have sex with men-referred to herein as sexual minority men (SMM)-compared to men who have sex with women only. Similarly, rates of HIV infection have increased among American Indian (AI) men. This is a two-group, active-control RCT of the online e-HERO intervention. Participants (100 SMM; 100 AI men) will be randomized into two groups in equal proportions. This study evaluates two versions of an online sexual health intervention. The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods (e.g., videos, interactive games) to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors. The control condition contains the same number of modules as e-HERO. The control condition contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently available on many websites, with the aim to understand how the cultural tailoring of e-HERO modules improves upon information that is readily available online.

Interventions

BEHAVIORALe-HERO: Ending the HIV Epidemic in Rural Oklahoma

A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.

Sponsors

Northern Arizona University
Lead SponsorOTHER
Oklahoma State University
CollaboratorOTHER
Purdue University
CollaboratorOTHER
National Institute on Minority Health and Health Disparities (NIMHD)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

Centralized, computer-based group assignment using permuted blocks.

Eligibility

Sex/Gender
MALE
Age
17 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

* Provide signed and dated informed consent form * Be willing and able to follow study procedures and instructions and be available for the duration of the study * Be between 17 and 29 years of age * Be American Indian or a gay, bisexual, or other man who has sex with men. American Indian status is self-identified-no tribal enrollment verification will be required. * Be a resident of Oklahoma, in a rural identified county

Exclusion criteria

* Anything that would place the individual at increased risk or preclude the individual's full compliance with, or completion of, the study. * HIV diagnosis

Design outcomes

Primary

MeasureTime frameDescription
HIV Testing UptakeAssessed at the end of month 3 of the intervention.HIV testing uptake is assessed through the request of an at-home rapid HIV test through the e-HERO platforms.

Secondary

MeasureTime frameDescription
HIV Testing IntentionBaseline, 1 month, and 3 monthsThe outcome scale name is called "Intentions to get tested for HIV", measuring the construct of intention to get tested for HIV in the next 3 months, by asking the 1-item question: "How likely are you to get tested for HIV in the next three months?" The outcome is assessed on a 6-point Likert-type scale.The score range was 1-6, from 1= Extremely unlikely to get tested for HIV to 6=Extremely likely to get tested for HIV. A higher score indicated greater intentions to get tested, which is considered a preferred outcome. There were no subscales.
STI Testing IntentionBaseline, 1 month, and 3 monthsThe outcome scale name is called "Intentions to get tested for a Sexually Transmitted Infection", measuring the construct of intentions to get a test for an STI in the next 3 months. The outcome was a 1-item question: "How likely are you to get tested for other STIs besides HIV in the next three months?" The answers were assessed on a 6-point Likert-type scale, with a score ranging from 1-6 (1= Extremely unlikely to get tested for an STI to 6=Extremely likely to get tested for an STI). A higher score indicated greater intentions to get tested, which is considered a preferred outcome. There were no subscales.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJulie Baldwin, Ph.D.

Northern Arizona University

Participant flow

Recruitment details

Recruitment occurred between Dec 1, 2022 and June 19, 2024.

Baseline characteristics

Characteristic
Age, Continuous23.35 Years
STANDARD_DEVIATION 4.14
Race (NIH/OMB)
American Indian or Alaska Native
7 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
39 Participants
Region of Enrollment
United States
37 Participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 350 / 37
other
Total, other adverse events
0 / 350 / 37
serious
Total, serious adverse events
0 / 350 / 37

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026